Introduction
============

The preoccupation with exploration of treatment options that may help attain a lighter skin tone or fairer complexion has been an ongoing phenomenon in people with skin of color (SOC). The direct implication of this craze is the exploitation of topical agents originally developed for treatment of hyperpigmentation, such as skin lightening therapies. Topicals containing hydroquinone, alpha and beta hydroxy acids, tretinoin, mequinol, arbutin, vitamin C, soy extracts and concoctions of multiple ingredients, including newer cosmeceuticals, are now in vogue for treatment of facial melanoses especially melasma \[[@b1-dp0801a04]\] and for general skin lightening, at least of the face, neck and other exposed parts. The local adverse effects of these agents \[[@b1-dp0801a04]\] and the quantity required for large surface area application constitute major limitations of this approach. Understandably, the effect of such locally applied topicals remains limited to the application site alone without any notable systemic skin lightening effect. The quest for a systemic skin-whitening agent ensues. Oral antioxidants, such as vitamin C, vitamin E, tranexamic acid, flavonoids, and various botanical extracts have been tried in melasma and disorders of hyperpigmentation, but none has proven to provide an overall skin lightening effect \[[@b1-dp0801a04],[@b2-dp0801a04]\].

Glutathione, being a strong antioxidant with additional anti-melanogenic properties, has recently become the most popular "systemic skin lightening molecule." The most "popular" and controversial route of administration of glutathione for skin lightening has been intravenous (IV). Glutathione (GSH), a low molecular weight thiol-tripeptide is central to the maintenance of intracellular redox balance \[[@b3-dp0801a04]\]. Currently, to the best of our knowledge, IV GSH has been approved by different statutory drug regulatory authorities for specific systemic disorders. The indications approved by the Central Drugs Standard Control Organization (CDSCO) in India are: 1) alcoholic fatty liver, 2) alcoholic liver fibrosis, 3) alcoholic liver cirrhosis, and 4) alcoholic hepatitis \[[@b4-dp0801a04]\]. The Philippines Food and Drug Administration (FDA) has approved its use as an adjunctive treatment to reduce neurotoxicity associated with cisplatin chemotherapy \[[@b5-dp0801a04]\]. In addition to it being one of the richest antioxidants, it is being promoted as a skin-lightening agent, following the discovery of its antimelanogenic properties \[[@b7-dp0801a04]\]. Amongst the many mechanisms postulated to contribute to its antimelanogenic properties ([Figure 1](#f1-dp0801a04){ref-type="fig"}), inhibition of tyrosinase enzyme, skewing of melanogenesis from the darker eumelanin to the lighter phaeomelanin, and scavenging of free radicals seem to be the most important \[[@b8-dp0801a04]\]. Unfortunately, there is a clear contradiction between the exact evidence supporting its efficacy and safety, and the hype around its depigmentary properties, with pharma-cosmeceuticals inundating dermatology therapeutics with glutathione tablets, capsules, topical preparations and parenteral preparations across the globe \[[@b9-dp0801a04]\].

Hailed for generations as a "magical skin whitening" molecule in countries like the Republic of Philippines, glutathione has seen a rapid spread in its popularity across the globe in a short duration of time. This has been the outcome of ardent manufacturer supported media campaigns about the almost preposterous effects of this molecule as a wonder drug for not only disorders of hyperpigmentation such as melasma, but also for general "skin whitening." This article is meant to update healthcare professionals about the current status of efficacy, safety, and evidence of different formulations of glutathione for skin tone lightening. For more detailed background information regarding the basic and applied physiology of glutathione, readers may refer to a previously published exhaustive article on this aspect \[[@b6-dp0801a04]\]. It is important to know that glutathione exists in a reduced form (GSH) and an oxidized form (GSSG). The reduced form, GSH, seems to be instrumental in the depigmenting properties of this unique molecule. Apart from these two major forms, GSH may be esterified to form glutathione esters \[[@b7-dp0801a04]\].

An evidence-update on glutathione as a skin-lightening agent
============================================================

At the time of authoring this article, there were only four published studies that evaluated the efficacy of oral, topical, and parenteral glutathione as a skin-whitening agent ([Table 1](#t1-dp0801a04){ref-type="table"}) \[[@b10-dp0801a04]--[@b13-dp0801a04]\]. The two trials on oral GSH, conducted in Thai population by Arjinpathana and Asawanonda, and in Filipino women by Handog et al. involved administering 500 mg/day of GSH in two divided doses to the study population, the difference being the use of a buccal lozenge (instead of oral capsules) in the latter study to enhance systemic absorption of glutathione \[[@b10-dp0801a04],[@b11-dp0801a04]\]. The primary efficacy outcome in both the trials was to evaluate the pre- and post-treatment melanin indices. Both trials employed a Mexameter MX 18 (Courage+Khazaka electronic GmbH, Cologne, Germany) to evaluate the primary efficacy outcome. The randomized, double-blind, two-arm, placebo-controlled study conducted by Arjinpathana and Asawanonda in 60 healthy medical students showed a consistent reduction in the melanin indices at all the six sites evaluated in the GSH group subjects, with a statistically significant reduction over placebo at two sites \[[@b10-dp0801a04]\]. The open-label, single-arm pilot study conducted by Handog et al. in 30 healthy Filipino women (aged 22--42 years) with Fitzpatrick skin types IV or V, using buccal lozenges instead of capsules of GSH, reported significant reduction in melanin index at both sun-exposed and sun-protected sites in all the subjects and moderate skin lightening observed by 90% of the subjects on global evaluation \[[@b11-dp0801a04]\]. The tolerance to GSH was excellent in both the studies. The singular randomized, double-blind, placebo-controlled clinical trial by Watanabe et al., conducted in 30 healthy Filipino women aged 30--50 years has provided virginal evidence favoring efficacy of topical GSSG 2% lotion (applied twice daily for 10 weeks) in producing temporary skin whitening \[[@b12-dp0801a04]\]. The results of this split-face, protocol-based study revealed statistically significant reduction of skin melanin index with glutathione compared to placebo, with no adverse drug effects. However, the results of these studies need to be interpreted with caution owing to certain limitations in their study design.

The major limitations of these studies included: small sample size, cohort consisting of healthy volunteers, extremely short study period with an even shorter follow-up, and lack of measurement of blood levels of glutathione \[[@b10-dp0801a04]--[@b12-dp0801a04]\]. Details of the inclusion criteria, methodology, results and specific limitations of these studies have been comprehensively catalogued in [Table 1](#t1-dp0801a04){ref-type="table"}.

Despite the rampant use of intravenous (IV) glutathione injections for skin lightening in certain countries, evidence favoring such a practice remains elusive. For years, the strong lobby of proponents of IV glutathione for skin lightening, including manufacturers, distributors, many skin clinics, and med spas, have been recommending arbitrary dosage schedules, despite complete lack of evidence \[[@b13-dp0801a04],[@b14-dp0801a04]\]. It is only recently, that Zubair et al. studied the efficacy and safety of IV GSH for skin tone lightening in 25 patients of Pakistani origin in a placebo-controlled trial (1,200 mg given IV twice a week for 6 weeks in the treatment group versus normal saline in control group) \[[@b15-dp0801a04]\]. Although the results from this singular trial did not favor IV glutathione as an effective or lasting treatment for skin tone lightening, the inherent flaws of the study design mandate cautious analysis. The small sample size (n=25 in each group), complicated with a high dropout rate from the treatment group (9 out of 25) in this trial exhorts a cautious interpretation of the results. The methodology was flawed due to the employment of a highly subjective visual Taylor scale for pre- and post-treatment evaluation of change in skin hue and tone and lack of mention of statistical tests applied. The Taylor scale is an unreliable tool for observing subtle changes in skin pigmentation with a very high inter-investigator variability in its interpretation \[[@b16-dp0801a04]\]. Results based on Taylor scale, rather than a reliable objective parameter like the melanin index using a Mexameter MX-18, at best, are speculative. Further, the major adverse effect reported in the IV GSH treated group was liver dysfunction, which was neither qualified nor quantified. Development of liver dysfunction in healthy individuals receiving IV GSH is surprising, since the medication is approved by the CDSCO for the treatment of various liver disorders mentioned earlier \[[@b4-dp0801a04]\]. The researchers also did not evaluate baseline or post-treatment renal nor thyroid function of the subjects, both of which were reported to be adversely affected by IV glutathione in the position paper by the FDA, Department of Health, Republic of the Philippines \[[@b5-dp0801a04]\].

The controversy surrounding absorption of oral glutathione and adverse effects of IV glutathione and statutory status
=====================================================================================================================

Glutathione-based oral dietary supplements have been accorded the status of "Generally Recognized as Safe (GRAS)" consistent with Section 201(s) of the Federal Food, Drug, and Cosmetic Act of the United States Food and Drug Administration (US-FDA) \[[@b16-dp0801a04]\]. There is no restriction on its availability in this form in the US, Philippines and Japan. Oral GSH is also easily available over-the-counter (OTC) in India and many other Asian countries. Since oral GSH is known to have a low bioavailability in humans \[[@b9-dp0801a04]\], manufacturers of IV injections of GSH "recommend" this route of administration to achieve desired therapeutic levels in the blood and skin rapidly to produce "instant" skin whitening results. However, as emphasized above, the literature evaluating the efficacy of IV GSH is still lacking. Furthermore, the duration of therapy and long-term efficacy is yet to be established. Despite the lack of evidence, manufacturers of IV GSH have been "recommending" a dose of 600--1200 mg, to be injected weekly or twice a week, with no specified net duration of the therapy \[[@b8-dp0801a04]\].

Although the overall safety of IV GSH, extrapolated from studies evaluating its use for male infertility and liver disorders seems to be convincing \[[@b18-dp0801a04],[@b19-dp0801a04]\], several adverse effects of IV GSH have been documented in the Philippines ([Figure 2](#f2-dp0801a04){ref-type="fig"}), detailed in the position paper by the FDA, Department of Health, Republic of the Philippines \[[@b5-dp0801a04]\] with a warning for the public on the subject of the safety of the off-label use of glutathione solution for injection ([Figure 3](#f3-dp0801a04){ref-type="fig"}). The reported adverse effects include adverse cutaneous eruptions including potentially fatal Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), severe abdominal pain, thyroid dysfunction, renal dysfunction, and lethal complications such as air embolism, or potentially fatal sepsis due to incorrect/unsterile method of IV administration and use of counterfeit GSH \[[@b5-dp0801a04],[@b9-dp0801a04]\]. Apart from the lack of evidence favoring IV GSH for skin lightening, the extremely high cost of injection vials constitutes another compelling deterrent to its use. The important limitations of IV GSH have been enumerated in [Figure 4](#f4-dp0801a04){ref-type="fig"}.

The pharmacological game changer: recent insights from research on the effect of GSH versus esterified GSH in tyrosinase inhibition
===================================================================================================================================

A reasonable intracellular concentration of GSH and its unimpeded transportation into the melanosomes are essential for GSH to inhibit tyrosinase and switch melanogenesis from eumelanin to pheomelanin. Trans-melanosomal transportation can be achieved through a membrane channel or diffusion, both of which seem to be lacking for GSH, a fact well established in previous research \[[@b20-dp0801a04],[@b21-dp0801a04]\]. Chung et al. recently evaluated the in vitro antimelanogenic effects and cytotoxicity of GSH and its three esterified derivatives---GSH monoethyl ester (GSH-MEE), GSH diethyl ester (GSH-DEE), and GSH monoisopropyl ester (GSH-MIPE)---in three cell culture lines \[[@b22-dp0801a04]\]. The results of their research demonstrated significant inhibitory effect of GSH-MEE and GSH-MIPE, but not GSH, on intracellular tyrosinase activity and melanin production. The authors attributed this effect to the lipophilicity of the esterified derivatives of GSH. Of the three esters, GSH-DEE and GSH-MIPE demonstrated additional cytotoxic activity, rendering them unsuitable for clinical use. Given in vitro efficacy and lack of cytotoxicity of GSH-MEE, the researchers suggested the development of GSH-MEE, instead of GSH, as an efficacious and safe molecule for the treatment of hyperpigmentation \[[@b22-dp0801a04]\]. However, these results need further validation in both in vitro and clinical trials before drawing definitive conclusions.

Conclusion
==========

There is little convincing evidence in favor of glutathione as a therapy for hyperpigmentation at the present time, and there are many unresolved controversies that surround its use ([Figure 5](#f5-dp0801a04){ref-type="fig"}). The trials available to date that have evaluated the role of glutathione in skin lightening administered through different modes have numerous limitations. Although the safety of topical and oral GSH seems to be good, their efficacy (especially long-term) remains questionable. The extant evidence to support or discourage use of IV GSH as a therapeutic modality for improving skin tone or pigmentation is minimal and contradictory; notwithstanding the austere concern regarding the potential adverse effects associated with this mode of administration. More evidence in the form of high quality trials with better study design, larger sample size, and long-term follow-up is vital, before our patients are subjected to glutathione-based treatments.
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###### 

Evidence of Glutathione as a Skin Lightening Agent: Current Summary of Studies Conducted to Date

  Glutathione Formulation                   Topical (GSSG cream)                                                                                                                                                                Oral (Capsules)                                                                                                              Oral / Buccal Lozenges                                                                                                                                              Intravenous
  ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors**                               Watanabe et al. \[[@b12-dp0801a04]\]                                                                                                                                                Arjinpathana & Asawanonda \[[@b10-dp0801a04]\]                                                                               Handog et al. \[[@b11-dp0801a04]\]                                                                                                                                  Zubair et al. \[[@b15-dp0801a04]\]
  **Study subjects**                        30 healthy Filipino womenAges: 30--50 years                                                                                                                                         60 healthy medical studentsAges: 19--22 years                                                                                30 healthy womenAges: 22--42 yearsFitzpatrick skin types IV or V                                                                                                    50 healthy Pakistani womenAges: 25--47 yearsSkin type not mentioned
  **Study design**                          Randomized, double-blind, placebo-controlled, Split-face study                                                                                                                      Randomized, double-blind, placebo-controlled study                                                                           Open-label, single-arm, pilot study                                                                                                                                 Open-label, placebo-controlled study
  **Methodology**                           Split-face study; application of 2% (w/w) GSSG lotion and placebo lotion, twice daily for 10 weeks                                                                                  Oral glutathione (500 mg) or placebo capsules daily, in 2 divided doses on an empty stomach for 4 weeks                      One buccal lozenge (500 mg) per day, for 8 weeks.                                                                                                                   Injection glutathione 1200 mg or normal saline (placebo) injected over 30 minutes
  **Frequency of evaluation**               Baseline; weekly for 10 weeks                                                                                                                                                       Baseline; and at 4 weeks                                                                                                     Baseline, twice weekly for 8 weeks                                                                                                                                  Baseline, twice weekly for 8 weeks
  **Primary outcome**                       Melanin index---by Mexameter MX18                                                                                                                                                   Melanin index---by Mexameter                                                                                                 Melanin index---by Mexameter                                                                                                                                        Visual Taylor hyperpigmentation scale
  **Subjective parameters**                 Global evaluation on a 7-point rating scale                                                                                                                                         Global evaluation s on a 4-point rating scale                                                                                Global evaluation on a 5-point rating scale                                                                                                                         None
  **Results**                               Melanin index Melanin index reduction significant in GSSG group vs. placeboOther parameters such as skin moisture, curvature index, keratin index also improved in the GSSG group   Melanin index Melanin index reduction significant at all six sites in oral GSH group vs. placebo                             Melanin index Melanin index reduction significant at all sites in buccal GSH group vs. placeboGlobal Assessment: 27 subjects (90%) noted moderate skin lightening   Taylor scale Improvement (IV GSH vs placebo): Completion of 12 injections---37.5% vs. 18.7%After 2 months: 18.7% vs. 12.5%After 4 months: 18.7% vs, 0%After 6 months: 6.2% vs. 0%
  **Tolerance & Safety**                    Very well toleratedNo significant adverse effects in either group                                                                                                                   Very well toleratedNo significant adverse effects in either group                                                            Very well toleratedNo significant adverse effects in either group                                                                                                   Adverse effects in all GSH treated patientsSerious---Liver dysfunction in 32% (8) patients and anaphylactic shock in 1 patient.
  **Follow-up After Completion of Study**   None                                                                                                                                                                                None                                                                                                                         None                                                                                                                                                                Done on 3 occasions---2nd, 4th, 6th month after treatment completion
  **Study Limitations**                     Small sample sizeShort duration of studySubjects: Healthy Filipino womenNo post-study follow up                                                                                     Small sample sizeShort duration of studySubjects: Healthy young adultsNo post-study follow upSerum GSH levels not measured   Small sample sizeShort duration of studySubjects: Healthy womenNo post-study follow upSerum GSH levels not measured.                                                Small sample sizePoor study designNo mention of statistical analysisOnly two sites evaluatedUnreliable method of efficacy evaluationNo information on baseline bio-chemical parametersNo details on hepatic adverse effects, nature, severity and recoverySerum GSH levels not measured

Modified from Table 1 published in: Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. *Indian J Dermatol Venereol Leprol.* 2016;82:262.
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